HCA
HCA
HCA Healthcare, Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $19.51B ▲ | $5B ▼ | $1.88B ▲ | 9.62% ▲ | $8.14 ▲ | $4.16B ▲ |
| Q3-2025 | $19.16B ▲ | $5.05B ▲ | $1.64B ▼ | 8.57% ▼ | $7.05 ▲ | $3.87B ▲ |
| Q2-2025 | $18.61B ▲ | $4.66B ▼ | $1.65B ▲ | 8.88% ▲ | $6.91 ▲ | $3.85B ▲ |
| Q1-2025 | $18.32B ▲ | $4.71B ▼ | $1.61B ▲ | 8.79% ▲ | $6.52 ▲ | $3.73B ▲ |
| Q4-2024 | $18.29B | $4.73B | $1.44B | 7.86% | $5.7 | $3.52B |
What's going well?
Revenue and profits are both up, with operating income and net income growing faster than sales. The company is buying back shares, which increases earnings per share for investors.
What's concerning?
Interest costs and 'other' expenses are still a drag on profits. Growth is steady but not accelerating, and margins are not expanding.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $1.04B ▲ | $60.72B ▲ | $63.49B ▲ | $-6.03B ▼ |
| Q3-2025 | $997M ▼ | $59.75B ▲ | $61.91B ▲ | $-5.33B ▼ |
| Q2-2025 | $1.04B ▼ | $59.54B ▼ | $60.77B ▲ | $-4.39B ▼ |
| Q1-2025 | $1.06B ▼ | $59.8B ▲ | $60.24B ▲ | $-3.52B ▼ |
| Q4-2024 | $1.93B | $59.51B | $58.96B | $-2.5B |
What's financially strong about this company?
They have a large base of physical assets and most of their assets are tangible. Inventory is not piling up, and their receivables are still being collected at a reasonable pace.
What are the financial risks or weaknesses?
Debt is extremely high, equity is negative, and cash is low compared to bills due soon. Liquidity is tight, and the company is relying heavily on borrowing to keep operating.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $1.88B ▲ | $2.36B ▼ | $-1.32B ▲ | $-999M ▲ | $43M ▼ | $870M ▼ |
| Q3-2025 | $1.64B ▼ | $4.42B ▲ | $-1.39B ▼ | $-2.97B ▲ | $58M ▲ | $3.13B ▲ |
| Q2-2025 | $1.89B ▲ | $4.21B ▲ | $-1.25B ▼ | $-3.09B ▼ | $-121M ▲ | $3.03B ▲ |
| Q1-2025 | $1.82B ▲ | $1.65B ▼ | $-1.03B ▲ | $-1.5B ▲ | $-873M ▲ | $660M ▼ |
| Q4-2024 | $1.44B | $2.56B | $-1.35B | $-2.16B | $-955M | $1.27B |
What's strong about this company's cash flow?
HCA remains profitable, with net income rising to $1.88 billion. The company continues to generate positive cash flow from operations and has enough cash to cover normal business needs.
What are the cash flow concerns?
Operating and free cash flow both fell by more than half compared to last quarter. The company is returning more cash to shareholders than it is generating, and had to borrow heavily to fund buybacks.
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
International | $450.00M ▲ | $460.00M ▲ | $480.00M ▲ | $470.00M ▼ |
Managed Care And Other Insurers | $9.04Bn ▲ | $9.12Bn ▲ | $9.27Bn ▲ | $9.54Bn ▲ |
Managed Medicaid | $880.00M ▲ | $900.00M ▲ | $950.00M ▲ | $970.00M ▲ |
Managed Medicare | $3.30Bn ▲ | $3.35Bn ▲ | $3.31Bn ▼ | $3.48Bn ▲ |
Medicaid | $1.19Bn ▲ | $1.44Bn ▲ | $1.78Bn ▲ | $1.50Bn ▼ |
Medicare | $2.90Bn ▲ | $2.80Bn ▼ | $2.73Bn ▼ | $2.85Bn ▲ |
Revenue by Geography
| Region | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
American Group | $6.33Bn ▲ | $6.49Bn ▲ | $6.69Bn ▲ | $6.93Bn ▲ |
Atlantic Group | $6.17Bn ▲ | $6.12Bn ▼ | $6.14Bn ▲ | $6.28Bn ▲ |
National Group | $5.07Bn ▲ | $5.20Bn ▲ | $5.53Bn ▲ | $5.49Bn ▼ |
Q4 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at HCA Healthcare, Inc.'s financial evolution and strategic trajectory over the past five years.
HCA combines accelerating revenue growth with improving profitability and strong cash generation. Its scale and dense network across many markets give it significant negotiating power and operating leverage. The company has a clear edge in data and analytics, reinforced by proprietary AI‑driven tools and a strategic partnership with Google Cloud. Ownership of Galen College of Nursing offers a unique solution to labor constraints, and rising free cash flow supports both substantial reinvestment in facilities and technology and meaningful returns of capital to shareholders.
The main financial risks center on leverage and liquidity. Debt levels and net debt have increased steadily, while shareholders’ equity has turned negative and retained earnings have been drawn down by heavy capital returns, leaving less of a balance‑sheet cushion. Liquidity ratios remain tight, so the company depends heavily on continued strong cash generation and access to capital markets. Operationally, HCA must navigate industry‑wide challenges such as labor shortages, wage pressures, regulatory uncertainty, and competition from both large systems and specialized providers. There is also execution risk around scaling complex technology and AI initiatives across such a large organization.
Based on the provided information, HCA appears to be a fundamentally strong operator with an improving income statement, robust cash flows, and a sophisticated innovation agenda, but with a more aggressive balance‑sheet posture than many peers. If management continues to translate its scale, technology investments, and nursing pipeline into better margins and cash flow, the company is well positioned to benefit from growing healthcare demand and the shift toward data‑driven care. However, the combination of high leverage, tight liquidity, and sector headwinds means that the forward path is not without risk, and future performance will hinge on disciplined capital allocation and successful execution of its operational and technology strategies.
About HCA Healthcare, Inc.
https://www.hcahealthcare.comHCA Healthcare, Inc., through its subsidiaries, provides health care services company in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $19.51B ▲ | $5B ▼ | $1.88B ▲ | 9.62% ▲ | $8.14 ▲ | $4.16B ▲ |
| Q3-2025 | $19.16B ▲ | $5.05B ▲ | $1.64B ▼ | 8.57% ▼ | $7.05 ▲ | $3.87B ▲ |
| Q2-2025 | $18.61B ▲ | $4.66B ▼ | $1.65B ▲ | 8.88% ▲ | $6.91 ▲ | $3.85B ▲ |
| Q1-2025 | $18.32B ▲ | $4.71B ▼ | $1.61B ▲ | 8.79% ▲ | $6.52 ▲ | $3.73B ▲ |
| Q4-2024 | $18.29B | $4.73B | $1.44B | 7.86% | $5.7 | $3.52B |
What's going well?
Revenue and profits are both up, with operating income and net income growing faster than sales. The company is buying back shares, which increases earnings per share for investors.
What's concerning?
Interest costs and 'other' expenses are still a drag on profits. Growth is steady but not accelerating, and margins are not expanding.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $1.04B ▲ | $60.72B ▲ | $63.49B ▲ | $-6.03B ▼ |
| Q3-2025 | $997M ▼ | $59.75B ▲ | $61.91B ▲ | $-5.33B ▼ |
| Q2-2025 | $1.04B ▼ | $59.54B ▼ | $60.77B ▲ | $-4.39B ▼ |
| Q1-2025 | $1.06B ▼ | $59.8B ▲ | $60.24B ▲ | $-3.52B ▼ |
| Q4-2024 | $1.93B | $59.51B | $58.96B | $-2.5B |
What's financially strong about this company?
They have a large base of physical assets and most of their assets are tangible. Inventory is not piling up, and their receivables are still being collected at a reasonable pace.
What are the financial risks or weaknesses?
Debt is extremely high, equity is negative, and cash is low compared to bills due soon. Liquidity is tight, and the company is relying heavily on borrowing to keep operating.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $1.88B ▲ | $2.36B ▼ | $-1.32B ▲ | $-999M ▲ | $43M ▼ | $870M ▼ |
| Q3-2025 | $1.64B ▼ | $4.42B ▲ | $-1.39B ▼ | $-2.97B ▲ | $58M ▲ | $3.13B ▲ |
| Q2-2025 | $1.89B ▲ | $4.21B ▲ | $-1.25B ▼ | $-3.09B ▼ | $-121M ▲ | $3.03B ▲ |
| Q1-2025 | $1.82B ▲ | $1.65B ▼ | $-1.03B ▲ | $-1.5B ▲ | $-873M ▲ | $660M ▼ |
| Q4-2024 | $1.44B | $2.56B | $-1.35B | $-2.16B | $-955M | $1.27B |
What's strong about this company's cash flow?
HCA remains profitable, with net income rising to $1.88 billion. The company continues to generate positive cash flow from operations and has enough cash to cover normal business needs.
What are the cash flow concerns?
Operating and free cash flow both fell by more than half compared to last quarter. The company is returning more cash to shareholders than it is generating, and had to borrow heavily to fund buybacks.
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
International | $450.00M ▲ | $460.00M ▲ | $480.00M ▲ | $470.00M ▼ |
Managed Care And Other Insurers | $9.04Bn ▲ | $9.12Bn ▲ | $9.27Bn ▲ | $9.54Bn ▲ |
Managed Medicaid | $880.00M ▲ | $900.00M ▲ | $950.00M ▲ | $970.00M ▲ |
Managed Medicare | $3.30Bn ▲ | $3.35Bn ▲ | $3.31Bn ▼ | $3.48Bn ▲ |
Medicaid | $1.19Bn ▲ | $1.44Bn ▲ | $1.78Bn ▲ | $1.50Bn ▼ |
Medicare | $2.90Bn ▲ | $2.80Bn ▼ | $2.73Bn ▼ | $2.85Bn ▲ |
Revenue by Geography
| Region | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
American Group | $6.33Bn ▲ | $6.49Bn ▲ | $6.69Bn ▲ | $6.93Bn ▲ |
Atlantic Group | $6.17Bn ▲ | $6.12Bn ▼ | $6.14Bn ▲ | $6.28Bn ▲ |
National Group | $5.07Bn ▲ | $5.20Bn ▲ | $5.53Bn ▲ | $5.49Bn ▼ |
Q4 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at HCA Healthcare, Inc.'s financial evolution and strategic trajectory over the past five years.
HCA combines accelerating revenue growth with improving profitability and strong cash generation. Its scale and dense network across many markets give it significant negotiating power and operating leverage. The company has a clear edge in data and analytics, reinforced by proprietary AI‑driven tools and a strategic partnership with Google Cloud. Ownership of Galen College of Nursing offers a unique solution to labor constraints, and rising free cash flow supports both substantial reinvestment in facilities and technology and meaningful returns of capital to shareholders.
The main financial risks center on leverage and liquidity. Debt levels and net debt have increased steadily, while shareholders’ equity has turned negative and retained earnings have been drawn down by heavy capital returns, leaving less of a balance‑sheet cushion. Liquidity ratios remain tight, so the company depends heavily on continued strong cash generation and access to capital markets. Operationally, HCA must navigate industry‑wide challenges such as labor shortages, wage pressures, regulatory uncertainty, and competition from both large systems and specialized providers. There is also execution risk around scaling complex technology and AI initiatives across such a large organization.
Based on the provided information, HCA appears to be a fundamentally strong operator with an improving income statement, robust cash flows, and a sophisticated innovation agenda, but with a more aggressive balance‑sheet posture than many peers. If management continues to translate its scale, technology investments, and nursing pipeline into better margins and cash flow, the company is well positioned to benefit from growing healthcare demand and the shift toward data‑driven care. However, the combination of high leverage, tight liquidity, and sector headwinds means that the forward path is not without risk, and future performance will hinge on disciplined capital allocation and successful execution of its operational and technology strategies.

CEO
Samuel N. Hazen
Compensation Summary
(Year 2024)
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 3 of 687
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Mizuho
Outperform
UBS
Buy
JP Morgan
Neutral
Argus Research
Buy
Wells Fargo
Equal Weight
Deutsche Bank
Buy
Grade Summary
Showing Top 6 of 20
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:14.89M
Value:$7.89B
BLACKROCK INC.
Shares:14.85M
Value:$7.87B
BLACKROCK, INC.
Shares:12.58M
Value:$6.66B
Summary
Showing Top 3 of 1,767

